ImmunoGen, Inc.

2021 Q1 Form 10-Q Financial Statement

#000155837021006659 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $283.1M $247.3M
YoY Change 14.48% -8.54%
Cash & Equivalents $283.1M $247.3M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $15.40M $7.700M
YoY Change 100.0% 14.93%
Inventory
Prepaid Expenses
Receivables $5.500M $2.800M
Other Receivables $15.50M $13.00M
Total Short-Term Assets $319.6M $270.7M
YoY Change 18.04% -6.58%
LONG-TERM ASSETS
Property, Plant & Equipment $5.417M $6.018M
YoY Change -9.99% -80.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.325M $6.831M
YoY Change 7.23% 84.62%
Total Long-Term Assets $26.39M $28.08M
YoY Change -6.03% -17.65%
TOTAL ASSETS
Total Short-Term Assets $319.6M $270.7M
Total Long-Term Assets $26.39M $28.08M
Total Assets $346.0M $298.8M
YoY Change 15.78% -7.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.92M $9.534M
YoY Change 35.47% 8.34%
Accrued Expenses $38.80M $27.20M
YoY Change 42.65% -1.81%
Deferred Revenue $51.52M $123.0K
YoY Change 41782.11%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.100M
YoY Change
Total Short-Term Liabilities $134.4M $85.51M
YoY Change 57.13% 39.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.100M
YoY Change -100.0% 0.0%
Other Long-Term Liabilities $2.480M $1.489M
YoY Change 66.55% -99.48%
Total Long-Term Liabilities $2.480M $1.489M
YoY Change 66.55% -99.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $134.4M $85.51M
Total Long-Term Liabilities $2.480M $1.489M
Total Liabilities $251.8M $302.9M
YoY Change -16.86% -13.82%
SHAREHOLDERS EQUITY
Retained Earnings -$1.400B -$1.300B
YoY Change 7.69%
Common Stock $1.460B $1.312B
YoY Change 11.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $94.12M -$4.103M
YoY Change
Total Liabilities & Shareholders Equity $346.0M $298.8M
YoY Change 15.78% -7.75%

Cashflow Statement

Concept 2021 Q1 2020 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000855654
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
194998000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
199941000
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
0-17999
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
ImmunoGen, Inc.
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-2726691
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
830 Winter Street
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2021Q1 dei City Area Code
CityAreaCode
781
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
895-0600
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2021Q1 dei Trading Symbol
TradingSymbol
IMGN
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
199942152
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
283120000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
293856000
CY2021Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
93000
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
35000
CY2021Q1 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
5405000
CY2020Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
11000
CY2021Q1 imgn Non Cash Royalty Receivable
NonCashRoyaltyReceivable
15533000
CY2020Q4 imgn Non Cash Royalty Receivable
NonCashRoyaltyReceivable
22451000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15421000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7901000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
319572000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
324254000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5417000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5760000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13648000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14072000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7325000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10986000
CY2021Q1 us-gaap Assets
Assets
345962000
CY2020Q4 us-gaap Assets
Assets
355072000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
12916000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9538000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2882000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4620000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32820000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29320000
CY2021Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.00045
CY2021Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
4000
CY2020Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
7000
CY2021Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2096000
CY2020Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2093000
CY2021Q1 imgn Deferred Financing Costs Liability Sale Of Future Royalties Current
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesCurrent
267000
CY2020 imgn Deferred Financing Costs Liability Sale Of Future Royalties Current
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesCurrent
319000
CY2021Q1 imgn Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
29007000
CY2020Q4 imgn Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
44357000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3117000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3146000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
51515000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
29249000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
134353000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
122323000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
58522000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
80860000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17878000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18651000
CY2021Q1 imgn Deferred Financing Costs Liability Sale Of Future Royalties Noncurrent
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesNoncurrent
525000
CY2020Q4 imgn Deferred Financing Costs Liability Sale Of Future Royalties Noncurrent
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesNoncurrent
584000
CY2021Q1 imgn Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
38609000
CY2020Q4 imgn Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
41082000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2480000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2586000
CY2021Q1 us-gaap Liabilities
Liabilities
251842000
CY2020Q4 us-gaap Liabilities
Liabilities
265502000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
199941000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
194998000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
1999000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1950000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1458012000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1419460000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1365891000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1331840000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
94120000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
89570000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
345962000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355072000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15706000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13287000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34413000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27408000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10209000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8864000
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
825000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
44622000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
37097000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28916000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23810000
CY2021Q1 us-gaap Investment Income Net
InvestmentIncomeNet
13000
CY2020Q1 us-gaap Investment Income Net
InvestmentIncomeNet
646000
CY2021Q1 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
4644000
CY2020Q1 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
5702000
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
24000
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
24000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-480000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-198000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-34051000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29088000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
198835000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
166947000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34051000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29088000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-76121000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29088000
CY2020Q1 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
240000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
97744000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3122000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-4103000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-24298000
CY2020Q2 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
425000
CY2020Q2 imgn Adjustment Related To Issuance Costs
AdjustmentRelatedToIssuanceCosts
-1000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3409000
CY2020Q2 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
45000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-24523000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-22374000
CY2020Q3 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
128000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3729000
CY2020Q3 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
149000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-42891000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
31388000
CY2020Q4 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
678000
CY2020Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96528000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3718000
CY2020Q4 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
149000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
89570000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-34051000
CY2021Q1 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
1286000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33492000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
CY2020Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
1426000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3674000
CY2021Q1 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
149000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
94120000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-34051000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-29088000
CY2021Q1 imgn Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
15545000
CY2020Q1 imgn Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
12997000
CY2021Q1 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
4644000
CY2020Q1 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
5702000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
551000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
529000
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
709000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3823000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3122000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
58000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7446000
CY2021Q1 imgn Increase Decrease In Customer Asset
IncreaseDecreaseInCustomerAsset
5394000
CY2020Q1 imgn Increase Decrease In Customer Asset
IncreaseDecreaseInCustomerAsset
752000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-2641000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7520000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2228000
CY2021Q1 imgn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
424000
CY2020Q1 imgn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
353000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3661000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3047000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3802000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-649000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1571000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3267000
CY2021Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3487000
CY2020Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
5253000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-72000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
78000
CY2021Q1 imgn Operating Lease Liability Amortization
OperatingLeaseLiabilityAmortization
-802000
CY2020Q1 imgn Operating Lease Liability Amortization
OperatingLeaseLiabilityAmortization
-702000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44621000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28315000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
893000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-893000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1405000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1286000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
240000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
70000
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
229000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33492000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
97744000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34778000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
97984000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10736000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
71074000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
293856000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176225000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
283120000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
247299000
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Nature of Business and Plan of Operations</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">ImmunoGen, Inc. (the Company) was incorporated in Massachusetts in 1981 and is focused on the development of antibody-drug conjugates (ADCs). The Company has generally incurred operating losses and negative cash flows from operations since inception, incurred a net loss of $34.1 million during the three months ended March 31, 2021, and has an accumulated deficit of approximately $1.4 billion as of March 31, 2021. The Company has primarily funded these losses through payments received from its collaborations and equity, convertible debt, and other financings. To date, the Company has no product revenue and management expects to continue to incur operating expenses related to research and development and potential commercialization of its portfolio over the next several years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">As of March 31, 2021, the Company had $283.1 million of cash and cash equivalents on hand. The Company anticipates that its current capital resources will enable it to meet its operational expenses and capital expenditures for more than twelve months after the date these financial statements were issued. The Company may raise additional funds through equity, debt, or other financings, or generate revenues from collaborators through a combination of upfront license payments, milestone payments, royalty payments, and research funding. There can be no assurance that the Company will be able to obtain additional equity, debt, or other financing or generate revenues from collaborators on terms acceptable to the Company or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition and require the Company to defer or limit some or all of its research, development, and/or clinical projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the development by its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, manufacturing and marketing limitations, complexities associated with managing collaboration arrangements, third-party reimbursements, and compliance with governmental regulations.</p>
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-34100000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1400000000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
283100000
CY2021Q1 imgn Current Capital Resources To Meet Operational Expenses And Capital Expenditures Expected Period
CurrentCapitalResourcesToMeetOperationalExpensesAndCapitalExpendituresExpectedPeriod
P12M
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
110000000.0
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.0047
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.0039
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.0014
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
110109000
CY2021Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
72000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
110037000
CY2019Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
3631000
CY2020Q1 us-gaap Contract With Customer Asset Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerAssetIncreaseDecreaseForContractAcquiredInBusinessCombination
0
CY2020Q1 us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
3000000
CY2020Q1 imgn Contract Asset Impact Of Netting
ContractAssetImpactOfNetting
359000
CY2020Q1 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
990000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
127432000
CY2020Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
283000
CY2020Q1 imgn Contract Liabilities Impact Of Netting
ContractLiabilitiesImpactOfNetting
361000
CY2020 imgn Number Of Trades Impacting Fair Value Of Financial Instruments
NumberOfTradesImpactingFairValueOfFinancialInstruments
0
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
127510000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
72000
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
283000
CY2021Q1 imgn Cash And Cash Equivalents Number Of Financial Institutions
CashAndCashEquivalentsNumberOfFinancialInstitutions
3
CY2021Q1 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
283100000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
293900000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
700000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2021Q1 imgn Number Of Trades Impacting Fair Value Of Financial Instruments
NumberOfTradesImpactingFairValueOfFinancialInstruments
0
CY2021Q1 imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
21320000
CY2020Q1 imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
19021000
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3553000
CY2020Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1428000
CY2021Q1 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
CY2020Q1 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
CY2021Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
CY2020Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
CY2021Q1 imgn Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
3
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
397000
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3945000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5389000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5510000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5470000
CY2021Q1 imgn Number Of Real Estate Leases
NumberOfRealEstateLeases
2
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000.0
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1400000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1400000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13600000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
21000000.0
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5490000
CY2021Q1 imgn Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1376000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
27180000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6185000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
20995000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
3100000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
1200000
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
300000

Files In Submission

Name View Source Status
0001558370-21-006659-index-headers.html Edgar Link pending
0001558370-21-006659-index.html Edgar Link pending
0001558370-21-006659.txt Edgar Link pending
0001558370-21-006659-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imgn-20210331.xsd Edgar Link pending
imgn-20210331x10q.htm Edgar Link pending
imgn-20210331x10q_htm.xml Edgar Link completed
imgn-20210331xex10d1.htm Edgar Link pending
imgn-20210331xex31d1.htm Edgar Link pending
imgn-20210331xex31d2.htm Edgar Link pending
imgn-20210331xex32.htm Edgar Link pending
imgn-20210331_cal.xml Edgar Link unprocessable
imgn-20210331_def.xml Edgar Link unprocessable
imgn-20210331_lab.xml Edgar Link unprocessable
imgn-20210331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending